Unraveling the role of nicotinamide phosphoribosyltransferase on lipids in atherosclerosis

References

• Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B cell colony-enhancing factor. Mol. Cell. Biol. 14(2), 1431–1437 (1994). ▪▪ Describes the cloning of nicotinamide phosphoribosyltransferase (NAMPT).
   Google Scholar
• Rongvaux A, Shea RJ, Mulks MH et al. Pre‑B cell colony‑enhancing factor, whose expression is up‑regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur. J. Immunol. 32(11), 3225–3234 (2002). ▪▪ Describes the enzymatic activity of NAMPT.
   Google Scholar
• Kim MK, Lee JH, Kim H et al. Crystal structure of visfatin/pre‑B cell colonyenhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti‑cancer agent FK‑866. J. Mol. Biol. 362(1), 66–77 (2006).
   Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708), 426–430 (2005).
   Google Scholar
• Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307(5708), 426–430; Retraction in: Fukuhara A, Matsuda M, Nishizawa M et al.Science 318(5850), 563 (2007).
   Google Scholar
• Moschen AR, Gerner RR, Tilg H. Pre‑B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity‑related disorders. Curr. Pharm. Des. 16(17), 1913–1920 (2010). ▪ An excellent review of NAMPT and obesity‑related diseases.
   Google Scholar
• Dahl TB, Holm S, Aukrust P, Halvorsen B. Visfatin/NAMPT: a multifaceted molecule with diverse roles in physiology and pathophysiology. Annu. Rev. Nutr. 32, 229–243 (2012).
   Google Scholar
• Curat CA, Wegner V, Sengenes C et al. Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 49(4), 744–747 (2006).
   Google Scholar
• Krzysik‑Walker SM, Ocon‑Grove OM, Maddineni SR, Hendricks GL 3rd, Ramachandran R. Is visfatin an adipokine or myokine? Evidence for greater visfatin expression in skeletal muscle than visceral fat in chickens. Endocrinology 149(4), 1543–1550 (2008).
   Google Scholar
• Garten A, Petzold S, Barnikol‑Oettler A et al. Nicotinamide phosphoribosyltransferase (NAMPT/PBEF/visfatin) is constitutively released from human hepatocytes. Biochem. Biophys. Res. Commun. 391(1), 376–381 (2010).
   Google Scholar
• Dahl TB, Yndestad A, Skjelland M et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 115(8), 972–980 (2007).
   Google Scholar
• Kawasaki E, Hokari F, Sasaki M, Sakai A, Koshinaka K, Kawanaka K. Role of local muscle contractile activity in the exerciseinduced increase in NR4A receptor mRNA expression. J. Appl. Physiol. 106(6), 1826–1831 (2009).
   Google Scholar
• McGlothlin JR, Gao L, Lavoie T et al. Molecular cloning and characterization of canine pre‑B cell colony‑enhancing factor. Biochem. Genet. 43(3–4), 127–141 (2005).
   Google Scholar
• Benito N, Moreno A, Filella X et al. Inflammatory responses in blood samples of human immunodeficiency virus‑infected patients with pulmonary infections. Clin. Diagn. Lab. Immunol. 11(3), 608–614 (2004).
   Google Scholar
• Hausenloy DJ. Drug discovery possibilities from visfatin cardioprotection? Curr. Opin Pharmacol. 9(2), 202–207 (2009).
   Google Scholar
• Bi J, Li H, Ye SQ, Ding S. Pre‑B cell colony‑enhancing factor exerts a neuronal protection through its enzymatic activity and the reduction of mitochondrial dysfunction in in vitro ischemic models. J. Neurochem. 120(2), 334–346 (2012).
   Google Scholar
• Zhai RG, Rizzi M, Garavaglia S. Nicotinamide/nicotinic acid mononucleotide adenylyltransferase, new insights into an ancient enzyme. Cell. Mol. Life Sci. 66(17), 2805–2818 (2009).
   Google Scholar
• Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. Trends Biochem. Sci. 32(1), 12–19 (2007).
   Google Scholar
• Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD‑dependent histone deacetylase. Nature 403(6771), 795–800 (2000).
   Google Scholar
• D’Amours D, Desnoyers S, D’Silva I, Poirier GG. Poly(ADP‑ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342 (Pt 2), 249–268 (1999).
   Google Scholar
• Kim MY, Zhang T, Kraus WL. Poly(ADPribosyl)ation by PARP‑1: ‘PAR‑laying’ NAD+ into a nuclear signal. Genes Dev. 19(17), 1951–1967 (2005).
   Google Scholar
• Griendling KK, Sorescu D, Ushio‑Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86(5), 494–501 (2000).
   Google Scholar
• Moschen AR, Kaser A, Enrich B et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J. Immunol. 178(3), 1748–1758 (2007).
   Google Scholar
• Burgos ES, Schramm VL. Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. Biochemistry 47(42), 11086–11096 (2008).
   Google Scholar
• Hara N, Yamada K, Shibata T, Osago H, Tsuchiya M. Nicotinamide phosphoribosyltransferase/visfatin does not catalyze nicotinamide mononucleotide formation in blood plasma. PLoS ONE 6(8), e22781 (2011).
   Google Scholar
• Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J. Pathol. 214(2), 161–178 (2008).
   Google Scholar
• Forman D, Bulwer BE. Cardiovascular disease: optimal approaches to risk factor modification of diet and lifestyle. Curr. Treat. Opt. Cardiovasc. Med. 8(1), 47–57 (2006).
   Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685–1695 (2005).
   Google Scholar
• Kutuk O, Basaga H. Inflammation meets oxidation: NF‑kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol. Med. 9(12), 549–557 (2003).
   Google Scholar
• Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 104(4), 503–516 (2001).
   Google Scholar
• Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104(3), 365–372 (2001).
   Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature 420(6917), 868–874 (2002).
   Google Scholar
• Duewell P, Kono H, Rayner KJ et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 464(7293), 1357–1361 (2010).
   Google Scholar
• Lo JC, Wang Y, Tumanov AV et al. Lymphotoxin beta receptor‑dependent control of lipid homeostasis. Science 316(5822), 285–288 (2007).
   Google Scholar
• Morin CL, Schlaepfer IR, Eckel RH. Tumor necrosis factor‑alpha eliminates binding of NF‑Y and an octamer‑binding protein to the lipoprotein lipase promoter in 3T3‑L1 adipocytes. J. Clin. Invest. 95(4), 1684–1689 (1995).
   Google Scholar
• Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473(7347), 317–325 (2011).
   Google Scholar
• Kadoglou NP, Sailer N, Moumtzouoglou A et al. Visfatin (NAMPT) and ghrelin as novel markers of carotid atherosclerosis in patients with Type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 118(2), 75–80 (2010).
   Google Scholar
• Liu SW, Qiao SB, Yuan JS, Liu DQ. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin. Endocrinol. (Oxf.) 71(2), 202–207 (2009).
   Google Scholar
• Axelsson J, Witasp A, Carrero JJ et al. Circulating levels of visfatin/pre‑B cell colony‑enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am. J. Kidney Dis. 49(2), 237–244 (2007).
   Google Scholar
• Lu LF, Yang SS, Wang CP et al. Elevated visfatin/pre‑B cell colony‑enhancing factor plasma concentration in ischemic stroke. J. Stroke Cerebrovasc. Dis. 18(5), 354–359 (2009).
   Google Scholar
• Aust G, Uptaite‑Patapoviene M, Scholz M, Richter O, Rohm S, Bluher M. Circulating Nampt and RBP4 levels in patients with carotid stenosis undergoing carotid endarterectomy (CEA). Clin. Chim. Acta 412(13–14), 1195–1200 (2011).
   Google Scholar
• Korner A, Garten A, Bluher M, Tauscher R, Kratzsch J, Kiess W. Molecular characteristics of serum visfatin and differential detection by immunoassays. J. Clin. Endocrinol. Metab. 92(12), 4783–4791 (2007).
   Google Scholar
• Dahl T, Ranheim T, Holm S, Berge R, Aukrust P, Halvorsen B. Nicotinamide phosphoribosyltransferase and lipid accumulation in macrophages. Eur. J. Clin. Invest. 41(10), 1098–1104 (2011).
   Google Scholar
• Tanny JC, Dowd GJ, Huang J, Hilz H, Moazed D. An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell 99(7), 735–745 (1999).
   Google Scholar
• Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC‑1alpha and SIRT1. Nature 434(7029), 113–118 (2005). ▪▪ Describes the role of PGC1α and SIRT1 in glucose homeostasis.
   Google Scholar
• Ozasa H, Ayaori M, Iizuka M et al. Pioglitazone enhances cholesterol efflux from macrophages by increasing ABCA1/ABCG1 expressions via PPARgamma/LXRalpha pathway: findings from in vitro and ex vivo studies. Atherosclerosis 219(1), 141–150 (2011).
   Google Scholar
• Stein S, Lohmann C, Schafer N et al. SIRT1 decreases Lox‑1‑mediated foam cell formation in atherogenesis. Eur. Heart J. 31(18), 2301–2309 (2010).
   Google Scholar
• Liu TF, Vachharajani VT, Yoza BK, McCall CE. NAD+‑dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol Chem. 287(31), 25758–25769 (2012).
   Google Scholar
• Olarescu NC, Ueland T, Lekva T et al. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. J. Clin. Endocrinol. Metab. 97(4), 1355–1362 (2012).
   Google Scholar
• Lorente‑Cebrian S, Bustos M, Marti A, Martinez JA, Moreno‑Aliaga MJ. Eicosapentaenoic acid stimulates AMPactivated protein kinase and increases visfatin secretion in cultured murine adipocytes. Clin. Sci. (Lond.) 117(6), 243–249 (2009).
   Google Scholar
• Yang CC, Deng SJ, Hsu CC et al. Visfatin regulates genes related to lipid metabolism in porcine adipocytes. J. Anim. Sci. 88(10), 3233–3241 (2010).
   Google Scholar
• Caton PW, Kieswich J, Yaqoob MM, Holness MJ, Sugden MC. Metformin opposes impaired AMPK and SIRT1 function and deleterious changes in core clock protein expression in white adipose tissue of genetically‑obese db/db mice. Diabetes Obes. Metab. 13(12), 1097–1104 (2011).
   Google Scholar
• Imai S. “Clocks” in the NAD world: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim. Biophys. Acta 1804(8), 1584–1590 (2010).
   Google Scholar
• Picard F, Kurtev M, Chung N et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR‑gamma. Nature 429(6993), 771–776 (2004).
   Google Scholar
• Rutanen J, Yaluri N, Modi S et al. SIRT1 mRNA expression may be associated with energy expenditure and insulin sensitivity. Diabetes 59(4), 829–835 (2010).
   Google Scholar
• Bowlby SC, Thomas MJ, D’Agostino RB Jr, Kridel SJ. Nicotinamide phosphoribosyl transferase (Nampt) is required for de novo lipogenesis in tumor cells. PLoS ONE 7(6), e40195 (2012).
   Google Scholar
• Musso G, Gambino R, Cassader M. Recent insights into hepatic lipid metabolism in non‑alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 48(1), 1–26 (2009).
   Google Scholar
• Dahl TB, Haukeland JW, Yndestad A et al. Intracellular nicotinamide phosphoribosyltransferase protects against hepatocyte apoptosis and is down‑regulated in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 95(6), 3039–3047 (2010).
   Google Scholar
• Sun B, Yang G, Yang M, Liu H, Boden G, Li L. Long‑term high‑fat diet links the regulation of the insulin‑sensitizing fibroblast growth factor‑21 and visfatin. Cytokine 59(1), 131–137 (2012).
   Google Scholar
• Zhang K, Li L, Qi Y et al. Hepatic suppression of Foxo1 and Foxo3 causes hypoglycemia and hyperlipidemia in mice. Endocrinology 153(2), 631–646 (2012).
   Google Scholar
• Tao R, Wei D, Gao H, Liu Y, DePinho RA, Dong XC. Hepatic FoxOs regulate lipid metabolism via modulation of expression of the nicotinamide phosphoribosyltransferase gene. J. Biol Chem. 286(16), 14681–14690 (2011).
   Google Scholar
• Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28(1), 91–106 (2007).
   Google Scholar
• Pfutzner A, Hanefeld M, Lubben G et al. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk – results from the PIOSTAT study. Horm. Metab. Res. 39(10), 764–768 (2007).
   Google Scholar
• Derdemezis C, Filippatos T, Tselepis A, Mikhailidis D, Elisaf M. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opin Pharmacother. 9(11), 1829–1837 (2008).
   Google Scholar
• Kostapanos MS, Derdemezis CS, Filippatos TD et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur. J. Pharmacol. 578(2–3), 249–252 (2008).
   Google Scholar
• Kadoglou NP, Tsanikidis H, Kapelouzou A et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with Type 2 diabetes mellitus. Metabolism 59(3), 373–379 (2010).
   Google Scholar
• Aigner E, Bachofner N, Klein K et al. Retinol‑binding protein 4 in polycystic ovary syndrome – association with steroid hormones and response to pioglitazone treatment. J. Clin. Endocrinol. Metab. 94(4), 1229–1235 (2009).
   Google Scholar
• Hammarstedt A, Pihlajamaki J, Rotter SV et al. Visfatin is an adipokine, but it is not regulated by thiazolidinediones. J. Clin. Endocrinol. Metab. 91(3), 1181–1184 (2006).
   Google Scholar
• Pfutzner A, Marx N, Walcher D, Lobig M, Seidel D, Forst T. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with Type 2 diabetes and coronary artery disease. Clin. Lab. 54(7–8), 237–241 (2008).
   Google Scholar
• Erdem G, Dogru T, Tasci I et al. The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 82(2), 214–218 (2008).
   Google Scholar
• McGee KC, Harte AL, da Silva NF et al. Visfatin is regulated by rosiglitazone in Type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes. PLoS ONE 6(6), e20287 (2011).
   Google Scholar